Jaguar Health financials
$6.02−21.82%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.5M | $11.7M | $9.8M | $12.0M | $4.3M | $9.4M | $5.8M | $4.4M | $4.4M | $141.5K |
| Gross profit | $7.7M | $9.7M | $7.7M | $9.9M | $2.0M | $6.1M | $2.0M | $1.7M | $3.5M | $89.6K |
| Gross margin | 67.2% | 83.3% | 79.1% | 83.1% | 46.2% | 65.1% | 33.9% | 37.4% | 79.8% | 63.3% |
| Operating income | -$45.1M | -$30.8M | -$34.3M | -$34.4M | -$40.7M | -$26.6M | -$28.9M | -$30.8M | -$34.2M | -$13.6M |
| Net income | -$53.6M | -$38.5M | -$41.3M | -$47.5M | -$52.6M | -$38.6M | -$44.7M | -$32.1M | -$22.0M | -$14.7M |
| Net margin | −465.4% | −329.3% | −423.1% | −396.9% | −1213.3% | −411.8% | −774.5% | −727.9% | −503.7% | −10410.9% |
| Diluted EPS | $-12059.25 | $-68612.25 | $-1162015.91 | $-23546900.83 | $-57415909.09 | $-146435950.41 | $-1319387913.22 | $-22444238119.83 | $-77801420454.55 | $-207572959710.74 |
| EBITDA | -$43.2M | -$28.9M | -$31.9M | -$32.4M | -$39.0M | -$24.4M | -$22.4M | -$24.3M | -$14.5M | -$13.5M |
| Operating cash flow | -$23.7M | -$29.4M | -$33.2M | -$33.1M | -$35.0M | -$15.3M | -$20.5M | -$22.7M | -$9.8M | -$14.4M |
| Free cash flow | -$23.7M | -$29.4M | -$33.2M | -$33.2M | -$35.0M | -$15.3M | — | -$22.7M | — | -$14.5M |
| Diluted shares | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $968.0K | $8.0M | $6.5M | $5.5M | $17.1M | $8.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $42.5M | $35.5M | $35.9M | $33.6M | $28.2M | $16.2M |
| Total assets | $38.3M | $53.4M | $50.8M | $47.5M | $53.3M | $42.8M |
| Total liabilities | $57.0M | $44.4M | $45.9M | $48.8M | $41.4M | $25.6M |
| Shareholders' equity | -$18.7M | $6.5M | $4.9M | -$1.4M | $11.9M | $17.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology